The Most Important Trade War Is on Prescription Drugs

INSIDE SOURCES

Other trade fronts grab bigger headlines, but the fight over whether other rich countries should pay market prices for American prescription drugs is truly a matter of life or death. Europe, Japan and other wealthy countries impose price controls on drugs that force the lion’s share of earnings on new, innovative drugs to come from Americans. Fixing this could more than double the world market for breakthrough cures and treatments, meaning many more would be developed.

President Trump has scored a victory with the United Kingdom, which agreed to a substantial increase in what it pays for U.S. brand drugs in the new US/UK trade agreement. Pressing this issue on all fronts with the rest of the world is a potentially massive health, economic and political opportunity.

Germany, Japan and France have ridden our innovative coattails for too long. They claim to be our allies, but just as they long shortchanged NATO by underfunding defense, they underfund investment in new medical treatments and cures through pricing regimes based on government price controls. Remarkably, because they underutilize generics and protect domestic generic manufacturers from competition, they tend to spend more on drugs overall than we do. But by spending less on innovative brand drugs, they force Americans to carry the burden of financing multi-billion-dollar drugs on our own.

I have partnered with Stephen Moore, Steve Forbes and Tomas Phillipson to call attention to this issue and support efforts to rectify it as one of the key planks of a project we call the Most Favored Patient Initiative, with comprehensive proposals to bring transparency, choice and competition into healthcare to lower prices and improve quality.

Through that project, we have released a scorecard that illustrates precisely the problem we face from foreign freeloading on American drug innovation.

Read more here.

Next
Next

Most favored patient sends letter to senate judiciary urging lawmakers to uphold strong pbm reforms